|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2006-3-10
|
|
pubmed:abstractText |
The subtle modification of a selection of Abeta42 inhibiting non-steroidal anti-inflammatory drugs (NSAIDs), through synthesis of the geminal dimethyl analogues, was anticipated to ablate their cyclooxygenase activity whilst maintaining Abeta42 inhibition. Methylflurbiprofen 6 exhibited similar in vitro Abeta42 inhibition to its parent NSAID Flurbiprofen and was further evaluated in the Tg2576 mouse model of Alzheimer's disease and an animal model of gastro-intestinal (GI) impairment, but proved unviable for further clinical development.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0960-894X
|
|
pubmed:author |
pubmed-author:BainGretchenG,
pubmed-author:BeherDirkD,
pubmed-author:ChenWeichaoW,
pubmed-author:JiangXiaohuiX,
pubmed-author:MunozBenitoB,
pubmed-author:PeacheyJamesJ,
pubmed-author:PrasitPeppiP,
pubmed-author:ShearmanMark SMS,
pubmed-author:St-JacquesRenéR,
pubmed-author:StockNicholasN,
pubmed-author:WilliamsonToni LTL,
pubmed-author:WrigleyJonathan D JJD
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2219-23
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:16455248-Administration, Oral,
pubmed-meshheading:16455248-Alzheimer Disease,
pubmed-meshheading:16455248-Amyloid beta-Peptides,
pubmed-meshheading:16455248-Animals,
pubmed-meshheading:16455248-Anti-Inflammatory Agents, Non-Steroidal,
pubmed-meshheading:16455248-Brain,
pubmed-meshheading:16455248-Cyclooxygenase Inhibitors,
pubmed-meshheading:16455248-Disease Models, Animal,
pubmed-meshheading:16455248-Flurbiprofen,
pubmed-meshheading:16455248-Mice,
pubmed-meshheading:16455248-Peptide Fragments
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent.
|
|
pubmed:affiliation |
Department of Chemistry, Merck Research Laboratories, 3535 General Atomics Ct, San Diego, CA 92121, USA. nick.stock@amirapharm.com
|
|
pubmed:publicationType |
Journal Article
|
